Научно-практическая ревматология

Расширенный поиск

Хронический артрит у больных, инфицированных вирусами гепатита В и С

Полный текст:

Список литературы

1. <div><p>Pan C.Q., Zhang J.X. Natural history and clinical consequences of Hepatitis В Virus Infection. Int. J. Med. Sci., 2005, 2(1), 36-40.</p><p>Chen S.L., Morgan T.R. The natural history of hepatitis С virus (HCV) infection. Int. J. Med. Sci., 2006, 3(2), 47-52.</p><p>Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis С virus infection in the United States. 1988 through 1994. N. Engl. J. Med., 1999, 19, 341(8), 556-562</p><p>Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J. Clin. Virol., 2005.34, suppl 1, Sl-3.</p><p>Lauer G.M., Walker B.D. Hepatitis С virus infection. N. Engl. J. Med., 2001, 5, 345(1), 41-52.</p><p>Zhang J., Zou S., Giulivi A. Epidemiology of hepatitis В in Canada. Can. J. Infect. Dis., 2001,12(6), 345350.</p><p>Ganem D., Prince A.M. Hepatitis В virus infection- natural history and clinical consequences. N. Engl. J. Med., 2004, 350(11), 1118-1129.</p><p>Galossi A., Guarisco R., Beilis L., Puoti C. Extrahepatic manifestations of chronic HCV infection. J. Gastrointestin. Liver Dis., 2007, 16(1), 65-73.</p><p>Sterling R.K., Bralow S. Extrahepatic manifestations of hepatitis С virus. Curr. Gastiventerol. Rep., 2006, 8(1), 53-59.</p><p>Zignego A.L., Ferri C., Giannini C. et al. Hepatitis С virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin’s lymphoma: evidence for a pathogenetic role. Arch Virol., 1997, 142(3), 545-555.</p><p>Sene D., Saadoun D., Lima! N. et at. Update in Hepatitis С virus associated extrahepatic manifestations. Rev. Med. Interne., 2007, 28(6), 388-393.</p><p>Sansonno D., Comacchiulo V, lacobelli A.R. et at. Localization of hepatitis С virus antigens in liver and skin tissues of chronic hepatitis С virus-infected patients with mixed cryoglobulinemia. Hepatology 1995, 21(2), 305-312</p><p>Daghestani L., Pomeroy C. Renal manifestations of hepatitis С infection. Am. J. Med., 1999,106(3), 347354</p><p>Johnson R.J., Gretch D.R., Yamabe H. et al. Membranoproliferative glomerulonephritis associated with hepatitis С virus infection. N. Engl. J. Med., 1993, 328(7), 465-470.</p><p>Ferri C., La Civita L., Cirafisi C. et al. Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations. J. Rheumatol., 1992, 19(6), 889-895.</p><p>Tembl J.I., Ferrer J. М., Sevilla М. T. el al. Neurologic complications associated with hepatitis С virus infection. Neurology, 1999, 53(4), 861-864.</p><p>Dammacco F., Sansonno D., Piccoli C. et al. The lymphoid system in hepatitis С vims infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy. Semin. Liver Dis., 2000, 20(2), 143-157.</p><p>Sata М., Nagao Y. Symposium on clinical aspects in hepatitis virus infection. 6. Hepatitis virus and extrahepatic manifestions—skin, mucosa, muscle, and hematopoietic organs. Intern. Med., 2001, 40(2), 185189.</p><p>Gumber S.C., Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann. Intern. Med., 1995, 123(8),615-620.</p><p>Loustaud-Ratti V, Lunel F. Extrahepatic manifestations of hepatitis С virus infection Rev. Prat., 2000, 50(10), 1089-1093.</p><p>Ramos-Casals М., Trejo 0., Garcia-Carrasco М., Font J. Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis С virus infection. Rheumatology (Oxford), 2003, 42(7), 818-828.</p><p>Strassburg C.P., Obermayer-Straub P., Manns M.P. Autoimmunity in hepatitis С and D virus infection. J. Viral. Hepat., 1996, 3(2), 49-59</p><p>Manns M.P, Obermayer-Straub P. Viral induction of autoimmunity: mechanisms and examples in hepatol- ogy. J. Viral. Hepat., 1997, 4suppl 2, 42-47.</p><p>Haddad J., Deny P., Munz-Gotheil C. et al. Lymphocytic sialadenitis of Sjogren’s syndrome associated with chronic hepatitis С virus liver disease. Lancet, 1992, 339(8789), 321-323.</p><p>Ramos-Casals М., De Vita S., Tzioufas A.G. Hepatitis С virus, Sjogren’s syndrome and В-cell lymphoma: linking infection, autoimmunity and cancer. Autoimmun. Rev., 2005, 4(1), 8-15</p><p>Giordano N., Amendola A., Papakostas P. et al. Immune and autoimmune disorders in HCV chronic liver disease: personal experience and commentary on literature. New Microbiol, 2005, 28(4), 311-317.</p><p>Banks S. E., Riley T.R. 3rd, NaidesS.J. Musculoskeletal complaints and serum autoantibodies associated with chronic hepatitis С and nonalcoholic fatty liver disease. Dig. Dis. Sci., 2007, 52(5), 1177-1182</p><p>Rosner I., Rozenbaum М., Toubi E. et al. The case for hepatitis С arthritis. Semin. Arthr. Rheum., 2004, 33(6), 375-387</p><p>Palazzi C., Olivieri I., Cacciatore P., etal. Management of hepatitis С virus-related arthritis. Expert Opin. Pharmacother., 2005, 6(1), 27-34</p><p>Zuckerman E., Yeshurun D. Rosner I. Management of hepatitis С virus-related arthritis. BioDrugs, 2001, 15(9), 573-584.</p><p>Fadda P., La Civita L., Zignego A.L., Ferri C. Hepatitis С virus infection and arthritis. A clinico- serological investigation of arthritis in patients with or without cryoglobulinemic syndrome Reumatismo, 2002, 54(4), 316-323</p><p>Zuckerman E., Keren D., Rozenbaum M. et al. Hepatitis С virus-related arthritis: characteristics and response to therapy with interferon alpha. Clin. Exp. Rheumatol., 2000 18(5), 579-584.</p><p>Lienesch D., Morris R., Metzger A. et at. Absence of cyclic citrullinated peptide antibody in nonar- thritic patients with chronic hepatitis С infection. J. Rheumatol., 2005, 32(3), 489-493.</p><p>Riedemann J.P., Munoz S., Kavanaugh A. The use of second generation anti-ССР antibody (anti-CCP2) testing in rheumatoid arthritis—a systematic review. Clin. Exp. Rheumatol., 2005, 23(5suppl39), S69-76</p><p>Bas S., Genevay S., Meyer O., Gabay C. Anti- cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford), 2003, 42(5),677-680</p><p>Meyer O., Labarre C., Dougados M. et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann. Rheum. Dis., 2003, 62(2), 120-126</p><p>Wener M.H., Hutchinson K, Morishima C., Gretch D. R. Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis С virus infection and cryoglobulinemia. Arthr. Rheum., 2004, 50(7), 2305-2308</p><p>Sene D., Ghillani-Dalbin P., Lima! N. et al. Anti- cyclic citrullinated peptide antibodies in hepatitis С virus associated rheumatological manifestations and Sjogren’s syndrome. Ann. Rheum. Dis., 2006, 65(3), 394-397. '</p><p>Bombardieri М., Alessandri C., Labbadia G., et al. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis С infection-associated polyarticular involvement. Arthr. Res. Ther., 2004, 6(2), R137-141.</p><p>Riccio A., Postiglione L., La Dogana P. et al. Anti- cyclic citrullinated peptide antibodies in patients affected by HCV-related arthritis. J. Biol. Regul. Homeost. Agents, 2008, 22(1), 57-61.</p><p>Nissen M.J., Fontanges E., Allam Y. et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford), 2005, 44(8), 1016-1020.</p><p>Weigand K., Stremmel W., Encke J. Treatment of hepatitis С virus infection. World J. Gastroenterol 2007, 13(13), 1897-1905</p><p>Manns M.P., McHutchison J.G., Gordon S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001, 358(9286), 958-965.</p><p>Tarantino G., Riccio A., Spand A. et al. HCV infection and chronic arthritis: Does viral replication matter? Hepatol. Res., 2006, 35(4), 238-241.</p><p>Marotte H., Fontanges E., Bailly F. et al. Etanercept treatment for three months is safe in patients with rheu- matological manifestations associated with hepatitis С virus. Rheumatology (Oxford), 2007, 46(1), 97-99.</p><p>Olesinska М., Chwalinska-Sadowska H. Rheumatic syndromes during the course of HCV infection. Pol. Merkur. Lekarski, 2002, 12(68),119-121.</p><p>Chuang E., Del Vecchio A., Smolinski S. et al. Biomedicines to reduce inflammation but not viral load in chronic HCV—what’s the sense ? Trends Biotechnol., 2004, 22(10), 517-523.</p><p>Larrea E., Garcia N., Qian C. et al. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology, 1996, 23(2), 210-217</p><p>Zein N.N., Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis С virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J. Hepatol, 2005, 42(3), 315-322</p><p>Roccatello D., Baldovino S., Rossi D. et al. Rituximab as a Therapeutic Tool in Severe Mixed Cryoglobulinemia. Clin. Rev. Allergy Immunol., 2008, 34(1), 111-117</p><p>Mason A. Role of viral replication in extraliepatic syndromes related to hepatitis В virus infection. Minerva Gastroenterol Dietol. 2006, 52(1), 53-66</p><p>Han SH. Extrahepatic manifestations of chronic hepatitis B. Clin. Liver Dis., 2004, 8(2), 403-418.</p><p>Gocke D.J. Extrahepatic manifestations of viral hepatitis. Am. J. Med. Sci., 1975, 270(1), 49-52</p><p>Toivanen A., Toivanen P. Which viruses should we look for in a recent onset polyarthritis. Acta Reumatol. Port., 2006, 31(1), 39-47.</p><p>Chi Z.C., Ma S.Z. Rheumatologic manifestations of hepatic diseases. Hepatobiliaiy Pancreat. Dis. Int., 2003, 2(1), 32-37</p><p>Lee S. I., Yoo W.H., Yun H.J. et al. Absence of antibody to cyclic citrullinated peptide in sera of non- arthritic patients with chronic hepatitis В virus infection. Clin. Rheumatol., 2007, 26(7), 1079-1082.</p><p>Coffin C.S., Lee S.S. Chronic hepatitis B—who should be treated? Med. Gen. Med., 2006, 8(1), 75.</p><p>Abraham S., Begum S., Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann. Rheum. Dis., 2004, 63(2), 123-129.</p><p>Maillefert J.F., Muller G., Falgarone G. et al. Prevalence of hepatitis С virus infection in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2002, 61(7), 635-637</p><p>Barbosa V.S., Silva N.A., Martins R.M. Hepatitis С virus seroprevalence and genotypes in patients with diffuse connective tissue diseases and spondyloarthropathies. Braz. J. Med. Biol. Res., 2005, 38(5),801-805</p><p>Mok M.Y., Ng W.L., Yuen M.F. et al. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin. Exp. Rheumatol., 2000, 18(3), 363-368.</p><p>Е.В.Шекшина, P.M.Балабанова Инфекция и ревматоидный артрит: некоторые аспекты диагностики и лечения. Инфекц. антимикроб, тер., 2003, 3, 3-8</p><p>Saag K.G., Teng G.G., Patkar N.M. et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthr. Rheum., 2008, 59(6), 762-784.</p><p>Kujawska A., Clements М., Wise С.М., Roberts W.N. Hepatitis С and methotrexate. Arthr. Rheum., 2003, 49(6), 843-845.</p><p>Roux C.H., Brocq 0., Breuil V. et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent В or С chronic hepatitis. Rheumatology (Oxford) 2006, 45(10), 12941297.</p><p>Peterson JR., Hsu F.C., Simkin P.A., Wener M.H. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis С infection. Ann. Rheum. Dis., 2003, 62(11), 1078-1082.</p><p>Parke F.A., Reveille J.D. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis С infection. Arthr. Rheum., 2004, 51(5), 800804.</p><p>Cansu DM., KaliJ'oglu Т., Korkmaz C. Short-term course of chronic hepatitis В and С under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J. Rheumatol., 2008, 35(3), 421-424.</p><p>Балабанова P.M., Вратских E.В. Эффективность комплексной терапии ревматоидного артрита с сопутствующим хроническим вирусным гепатитом С. Научно-практич. ревматол., 2003, 3, 74-76</p><p>M/son L.E., Widman D., Dikman S.H., Gorevic P.D. Autoimmune disease complicating antiviral therapy for hepatitis С virus infection. Semin. Arthr. Rheum., 2002, 32(3), 163-173.</p><p>Sood A., Mid ha V., Sood N. Rheumatoid arthritis probably induced by pegylated interfemn in a patient with chronic hepatitis C. Indian J. Gastroenterol., 2004, 23(1), 28-29.</p><p>Passos de Souza E., Evangelista Segundo P. Т., Jose F. F. et al. Rheumatoid arthritis induced by alpha- interferon therapy. Clin. Rheumatol., 2001, 20(4),297- 299</p><p>Niewold T.B., Gibofsky A. Concomitant interferon- alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C. Arthr. Rheum., 2006, 54(7), 2335-2337.</p><p>Thong B.Y., Koh E.T., Chng H.H., Chow W.C. Outcomes of chronic hepatitis В infection in Oriental patients with rheumatic diseases. Ann. Acad. Med. Singapore, 2007, 36(2), 100-105.</p><p>Helbling В., Reichen J. Reactivation of hepatitis В following withdrawal of chloroquine. Schweiz. Med. Wochenschr., 1994, 124(18), 759-762.</p><p>Tsai F.C., Hsieh S.C., Chen D.S. et al. Reactivation of hepatitis В virus in rheumatologic patients receiving immunosuppressive agents. Dig. Dis. Sci., 2006, 51(9), 1627-1632.</p><p>I to S., Nakazono K, Murasawa A. etal. Development of fulminant hepatitis В (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthr. Rheum., 2001, 44(2), 339-342</p><p>Ostuni P. Botsios C., Punzi L. et al. Hepatitis В reactivation in a chronic hepatitis В surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann. Rheum. Dis., 2003, 62(7), 686-687.</p><p>Tsutsumi Y., Kanamori H., Mori A. etal. Reactivation of hepatitis В virus with rituximab. Expert Opin. Drug Saf, 2005, 4(3), 599-608.</p><p>KatzL.H., Fraser A., Gafter-GviliA., etal. Lamivudine prevents reactivation of hepatitis В and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J. Viral. Hepat., 2008, 15(2), 89-102.</p><p>Michel М., Duvoux C., Hezode C., Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis В virus treated for an adult onset still’s disease. J. Rheumatol., 2003, 30(7), 1624-1625</p><p>Hagiyama H., Kubota Т., Komano Y. etal. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis В virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin. Exp. Rheumatol., 2004, 22(3), 375-376.</p><p>Gwak G. Y, Koh K.C., Kim H. Y. Fatal hepatic failure associated with hepatitis В virus reactivation in a hepatitis В surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin. Exp. Rheumatol., 2007, 25(6), 888-889</p><p>Maillefert J.F., Sibilia J., Toussirot E. et al. Rheumatic disorders developed after hepatitis В vaccination. Rheumatology’ (Oxford), 1999, 38(10), 978-983.</p><p>Pope J.E., Stevens A., Howson W., Bell D.A. The development of rheumatoid arthritis after recombinant hepatitis В vaccination. J. Rheumatol., 1998, 25(9), 1687-1693</p><p>Sibilia J., Maillefert J.F. Vaccination and rheumatoid arthritis. Ann. Rheum. Dis., 2002, 61(7), 575-576.</p><p>Elkayam 0., Yaron М., Caspi D. Safety and efficacy of vaccination against hepatitis В in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2002, 61(7), 623625</p></div><br />

Для цитирования:

Олюнин Ю.А. Хронический артрит у больных, инфицированных вирусами гепатита В и С. Научно-практическая ревматология. 2008;46(5):39-46.

For citation:

Olyunin Y.A. Chronic arthritis in patients with hepatitis virus В and С infection. Rheumatology Science and Practice. 2008;46(5):39-46. (In Russ.)

Просмотров: 404

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)